Wave Life Sciences Ltd. Ordinary Shares WVE
Analyst Ratings
- Consensus
- Buy — 13 Buy · 1 Hold · 0 Sell (14 analysts)
- Avg. Price Target
- $26.00 (+570.1% upside)
Key Stats
- Today's Range
- $3.86 – $4.01
- 50-Day Range
- $3.86 – $6.41
- 52-Week Range
- $3.86 – $21.73
- Volume
- 345K shs
- Average Volume
- 3.19 million shs
- Market Cap
- $778.34 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.72
- Price / Sales
- 11.91
Short Interest
- Short Interest
- 1.22%
- Days to Cover
- 14.12
Financials (TTM)
- Revenue
- $65.37 million
- Net Income
- $-202,473,000
- Net Margin
- -309.73%
- Return on Equity
- -44.64%
- Debt-to-Equity
- —
About Wave Life Sciences Ltd. Ordinary Shares
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Related Stocks
Compare head-to-head: WVE vs LLY·WVE vs JNJ·WVE vs ABBV·WVE vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.